NCT00337545已完成2 期
Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 2
研究概览
简要总结
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
详细描述
Study is completed and closed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
- •Measurable disease
排除标准
- •CNS disease
- •Chemotherapy or radiotherapy < 4 weeks prior
- •Active bleeding diathesis
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
Study of RAD001 in Advanced Cholangiocarcinoma: RADiCholCholangiocarcinomaNCT00973713Austin Health27
已完成
2 期
RAD001 in Advanced SarcomaSoft Tissue SarcomasBone SarcomasNCT01830153Asan Medical Center41
已完成
2 期
Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyLymphoma, Mantle- CellNCT00702052Novartis Pharmaceuticals58
已完成
4 期
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCarcinoma, Large CellNeuroendocrine TumorsNCT01317615Novartis Pharmaceuticals49
终止
2 期
Phase II Study of RAD001 Head and Neck CancerSquamous Cell Carcinoma of the Head and NeckNCT01051791Julie E. Bauman, MD, MPH13